Detection and treatment of long-chain omega-3 fatty acid deficiency in adolescents with SSRI-resistant major depressive disorder

PharmaNutrition

Volumn 2, Issue 2, 2014, Pages 38-46

  McNamara, Robert K ^a   Strimpfel, Jennifer ^a   Jandacek, Ronald ^a   Rider, Therese ^a   Tso, Patrick ^a   Welge, Jeffrey A ^a   Strawn, Jeffrey R ^a   DelBello, Melissa P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Adolescents; Docosahexaenoic acid; Eicosapentaenoic acid; Erythrocyte; Major depressive disorder (MDD); Omega 3 fatty acids

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DOCOSAHEXAENOIC ACID; ESCITALOPRAM; FATTY ACID; FISH OIL; FLUOXETINE; ICOSAPENTAENOIC ACID; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; ERYTHROCYTE; ESSENTIAL FATTY ACID DEFICIENCY; FEMALE; GAS CHROMATOGRAPHY; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; LETHARGY; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; NOSE OBSTRUCTION; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SLEEP DISORDER; SYMPTOMATOLOGY; VOMITING;

EID: 84897890508     PISSN: 22134344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phanu.2014.02.002     Document Type: Article

References (63)

1. McNamara R.K. Developmental long-chain omega-3 fatty acid deficiency and prefrontal cortex pathology in psychiatric disorders. Prefrontal cortex: developmental differences and role in neurological disorders 2013, 1-38. Nova Science Publishers, USA. R.O. Collins, J.L. Adams (Eds.).
2. Hibbeln J.R. Fish consumption and major depression. Lancet 1998, 351:1213. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/S0140-6736(05)79168-6.
3. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. British Journal of Psychiatry: The Journal of Mental Science 2004, 184:404-408. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1192/bjp.184.5.404.
4. Appleton K.M., Rogers P.J., Ness A.R. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. American Journal of Clinical Nutrition 2010, 91:757-770. http://www.ncbi.nlm.nih.gov/pubmed/, 10.3945/ajcn.2009.28313.
5. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry 2006, 67:1954-1967. http://www.ncbi.nlm.nih.gov/pubmed/, 10.4088/JCP.v67n1217.
6. Lin P.Y., Su K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. Journal of Clinical Psychiatry 2007, 68:1056-1061. http://www.ncbi.nlm.nih.gov/pubmed/, 10.4088/JCP.v68n0712.
7. Martins J.G. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. Journal of the American College of Nutrition 2009, 28:525-542. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1080/07315724.2009.10719785.
8. Sublette M.E., Ellis S.P., Geant A.L., Mann J.J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. Journal of Clinical Psychiatry 2011, 72:1577-1584. http://www.ncbi.nlm.nih.gov/pubmed/, 10.4088/JCP.10m06634.
9. Burke K.C., Burke J.D., Rae D.S., Regier D.A. Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations. Archives of General Psychiatry 1991, 48:789-795. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1001/archpsyc.1991.01810330013002.
10. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62:593-602. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1001/archpsyc.62.6.593.
11. Harel Z., Riggs S., Vaz R., White L., Menzies G. Omega-3 polyunsaturated fatty acids in adolescents: knowledge and consumption. Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine 2001, 28:10-15. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/S1054-139X(00)00179-8.
12. O'Sullivan T.A., Ambrosini G., Beilin L.J., Mori T.A., Oddy W.H. Dietary intake and food sources of fatty acids in Australian adolescents. Nutrition (Burbank, Los Angeles County, CA) 2011, 27:153-159. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.nut.2009.11.019.
13. Sichert-Hellert W., Wicher M., Kersting M. Age and time trends in fish consumption pattern of children and adolescents, and consequences for the intake of long-chain n-3 polyunsaturated fatty acids. European Journal of Clinical Nutrition 2009, 63:1071-1075. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1038/ejcn.2009.40.
14. Clayton E.H., Hanstock T.L., Hirneth S.J., Kable C.J., Garg M.L., Hazell P.L. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. European Journal of Clinical Nutrition 2009, 63:1037-1040. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1038/ejcn.2008.81.
15. Nemets H., Nemets B., Apter A., Bracha Z., Belmaker R.H. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. American Journal of Psychiatry 2006, 163:1098-1100. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1176/appi.ajp.163.6.1098.
16. Wozniak J., Biederman J., Mick E., Waxmonsky J., Hantsoo L., Best C., et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2007, 17:440-447. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.euroneuro.2006.11.006.
17. Harris W.S., von Schacky C., Park Y. Standardizing methods for assessing omega-3 fatty acid biostatus. The omega-3 fatty acid deficiency syndrome: opportunities for disease prevention 2013, 385-398. Nova Science Publishers, USA. R.K. McNamara (Ed.).
18. Fekete K., Marosvölgyi T., Jakobik V., Decsi T. Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans: a systematic review. American Journal of Clinical Nutrition 2009, 89:2070S-2084S. http://www.ncbi.nlm.nih.gov/pubmed/, 10.3945/ajcn.2009.27230I.
19. Sands S.A., Reid K.J., Windsor S.L., Harris W.S. The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 2005, 40:343-347. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1007/s11745-006-1392-2.
20. Itomura M., Fujioka S., Hamazaki K., Kobayashi K., Nagasawa T., Sawazaki S., et al. Factors influencing EPA+DHA levels in red blood cells in Japan. In Vivo 2008, 22:131-135.
21. Harris W.S., Pottala J.V., Varvel S.A., Borowski J.J., Ward J.N., McConnell J.P. Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: observations from 160,000 patients. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2013, 88:257-263. 10.1016/j.plefa.2012.12.004.
22. Barceló-Coblijn G., Murphy E.J., Othman R., Moghadasian M.H., Kashour T., Friel J.K. Flaxseed oil and fish-oil capsule consumption alters human red blood cell n-3 fatty acid composition: a multiple-dosing trial comparing 2 sources of n-3 fatty acid. American Journal of Clinical Nutrition 2008, 88:801-809. http://www.ncbi.nlm.nih.gov/pubmed/.
23. Flock M.R., Skulas-Ray A.C., Harris W.S., Etherton T.D., Fleming J.A., Kris-Etherton P.M. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. Journal of the American Heart Association 2013, 2:e000513. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1161/JAHA.113.000513.
24. Harris W.S., Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease?. Preventive Medicine 2004, 39:212-220. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.ypmed.2004.02.030.
25. Lin P.Y., Huang S.Y., Su K.P. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biological Psychiatry 2010, 68:140-147. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.biopsych.2010.03.018.
26. McNamara R.K., Jandacek R., Rider T., Tso P., Dwivedi Y., Pandey G.N. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. Journal of Affective Disorders 2010, 126:303-311. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.jad.2010.03.015.
27. Pottala J.V., Talley J.A., Churchill S.W., Lynch D.A., von Schacky C., Harris W.S. Red blood cell fatty acids are associated with depression in a case-control study of adolescents. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2012, 86:161-165. 10.1016/j.plefa.2012.03.002.
28. McNamara R.K., Strawn J.R. Role of long-chain omega-3 fatty acids in psychiatric practice. PharmaNutrition 2013, 1:41-49. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.phanu.2012.10.004.
29. Arango V., Underwood M.D., Mann J.J. Serotonin brain circuits involved in major depression and suicide. Progress in Brain Research 2002, 136:443-453. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/S0079-6123(02)36037-0.
30. Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Progress in Neuro-psychopharmacology & Biological Psychiatry 2003, 27:85-102. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/S0278-5846(02)00338-X.
31. Kodas E., Galineau L., Bodard S., Vancassel S., Guilloteau D., Besnard J.C., et al. Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat. Journal of Neurochemistry 2004, 89:695-702. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1471-4159.2004.02401.x.
32. DeMar J.C., Ma K., Bell J.M., Igarashi M., Greenstein D., Rapoport S.I. One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. Journal of Lipid Research 2006, 47:172-180. http://www.ncbi.nlm.nih.gov/pubmed/.
33. Chalon S., Delion-Vancassel S., Belzung C., Guilloteau D., Leguisquet A.M., Besnard J.C., et al. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. Journal of Nutrition 1998, 128:2512-2519. http://www.ncbi.nlm.nih.gov/pubmed/.
34. Vancassel S., Leman S., Hanonick L., Denis S., Roger J., Nollet M., et al. n-3 polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. Journal of Lipid Research 2008, 49:340-348. http://www.ncbi.nlm.nih.gov/pubmed/.
35. Carlezon W.A., Mague S.D., Parow A.M., Stoll A.L., Cohen B.M., Renshaw P.F. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biological Psychiatry 2005, 57:343-350. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.biopsych.2004.11.038.
36. Laino C.H., Fonseca C., Sterin-Speziale N., Slobodianik N., Reinés A. Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine. European Journal of Pharmacology 2010, 648:117-126. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.ejphar.2010.08.047.
37. Lakhwani L., Tongia S.K., Pal V.S., Agrawal R.P., Nyati P., Phadnis P. Omega-3 fatty acids have antidepressant activity in forced swimming test in Wistar rats. Acta Poloniae Pharmaceutica 2007, 64:271-276. http://www.ncbi.nlm.nih.gov/pubmed/.
38. Gertsik L., Poland R.E., Bresee C., Rapaport M.H. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. Journal of Clinical Psychopharmacology 2012, 32:61-64. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1097/JCP.0b013e31823f3b5f.
39. Jazayeri S., Tehrani-Doost M., Keshavarz S.A., Hosseini M., Djazayery A., Amini H., et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Australian & New Zealand Journal of Psychiatry 2008, 42:192-198. 10.1080/00048670701827275.
40. Kennard B., Silva S., Vitiello B., Curry J., Kratochvil C., Simons A., et al. Remission and residual symptoms after short-term treatment in the treatment of adolescents with Depression Study (TADS). Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45:1404-1411. TADS Team. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1097/01.chi.0000242228.75516.21.
41. Emslie G.J., Rush A.J., Weinberg W.A., Kowatch R.A., Hughes C.W., Carmody T., et al. A double-blind, randomized placebo-controlled trial of fluoxetine in depressed children and adolescents with depression. Archives of General Psychiatry 1997, 54:1031-1037. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1001/archpsyc.1997.01830230069010.
42. Fergusson D.M., Woodward L.J. Mental health, educational, and social role outcomes of adolescents with depression. Archives of General Psychiatry 2002, 59:225-231. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1001/archpsyc.59.3.225.
43. Bridge J.A., Goldstein T.R., Brent D.A. Adolescent suicide and suicidal behavior. Journal of Child Psychology and Psychiatry, and Allied Disciplines 2006, 47:372-394. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1469-7610.2006.01615.x.
44. Geller B., Zimerman B., Williams M., Bolhofner K., Craney J.L., DelBello M.P., et al. Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. Journal of the American Academy of Child and Adolescent Psychiatry 2001, 40:450-455. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1097/00004583-200104000-00014.
45. Sorgi P.J., Hallowell E.M., Hutchins H.L., Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutrition Journal 2007, 6:16. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1186/1475-2891-6-16.
46. Mayes T.L., Bernstein I.H., Haley C.L., Kennard B.D., Emslie G.J. Psychometric properties of the Children's Depression Rating Scale-Revised in adolescents. Journal of Child and Adolescent Psychopharmacology 2010, 20:513-516. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1089/cap.2010.0063.
47. Poznanski E.O., Cook S.C., Carroll B.J., Corzo H. Use of the children's Depression Rating Scale in an inpatient psychiatric population. Journal of Clinical Psychiatry 1983, 44:200-203. http://www.ncbi.nlm.nih.gov/pubmed/.
48. Klein R.G., Abikoff H., Barkley R.A. Clinical trials in children and adolescents. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines 1994, Raven, New York. R.F. Prien, D.S. Robinson (Eds.).
49. Kinrys G. Hypomania associated with omega3 fatty acids. Archives of General Psychiatry 2000, 57:715-716.
50. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry: The Journal of Mental Science 1978, 133:429-435. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1192/bjp.133.5.429.
51. Carver J.D., Benford V.J., Han B., Cantor A.B. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Research Bulletin 2001, 56:79-85. 10.1016/S0361-9230(01)00551-2.
52. Connor W.E., Neuringer M., Lin D.S. Dietary effects on brain fatty acid composition: the reversibility of n -3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. Journal of Lipid Research 1990, 31:237-247. http://www.ncbi.nlm.nih.gov/pubmed/.
53. Conklin S.M., Runyan C.A., Leonard S., Reddy R.D., Muldoon M.F., Yao J.K. Age-related changes of n-3 and n-6 polyunsaturated fatty acids in the anterior cingulate cortex of individuals with major depressive disorder. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2010, 82:111-119. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.plefa.2009.12.002.
54. McNamara R.K., Hahn C.-G., Jandacek R., Rider T., Tso P., Stanford K.E., et al. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biological Psychiatry 2007, 62:17-24. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.biopsych.2006.08.026.
55. McNamara R.K., Jandacek R., Tso P., Dwivedi Y., Ren X., Pandey G.N. Lower docosahexaenoic acid concentrations in the postmortem prefrontal cortex of adult depressed suicide victims compared with controls without cardiovascular disease. Journal of Psychiatric Research 2013, 47:1187-1191. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.jpsychires.2013.05.007.
56. McNamara R.K., Able J.A., Jandacek R., Rider T., Tso P., Eliassen J.C., et al. Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study. American Journal of Clinical Nutrition 2010, 91:1060-1067. http://www.ncbi.nlm.nih.gov/pubmed/, 10.3945/ajcn.2009.28549.
57. McNamara R.K., Jandacek R., Tso P., Weber W., Chu W.J., Strakowski S.M., et al. Low docosahexaenoic acid status is associated with reduced indices of cortical integrity in the anterior cingulate of healthy male children: a 1H MRS study. Nutritional Neuroscience 2013, 16:183-190. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1179/1476830512Y.0000000045.
58. McNamara R.K., Able J.A., Rider T., Tso P., Jandacek R. Effect of chronic fluoxetine treatment on male and female rat erythrocyte and prefrontal cortex fatty acid composition. Progress in Neuro-psychopharmacology & Biological Psychiatry 2010, 34:1317-1321. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.pnpbp.2010.07.016.
59. Assies J., Pouwer F., Lok A., Mocking R.J., Bockting C.L., Visser I., et al. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS ONE 2010, 5:e10635. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1371/journal.pone.0010635.
60. Liu J.J., Galfalvy H.C., Cooper T.B., Oquendo M.A., Grunebaum M.F., Mann J.J., et al. Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders. Journal of Clinical Psychiatry 2013, 74:732-738. http://www.ncbi.nlm.nih.gov/pubmed/, 10.4088/JCP.12m07970.
61. Clayton E.H., Hanstock T.L., Hirneth S.J., Kable C.J., Garg M.L., Hazell P.L. Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder. Lipids 2008, 43:1031-1038. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1007/s11745-008-3224-z.
62. Adams P.B., Lawson S., Sanigorski A., Sinclair A.J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996, 31(Suppl):S157-S161. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1007/BF02637069.
63. Edwards R., Peet M., Shay J., Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders 1998, 48:149-155. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/S0165-0327(97)00166-3.